Business Description
TELA Bio Inc
NAICS : 334510
SIC : 3845
ISIN : US8723811084
Share Class Description:
TELA: Ordinary SharesTotal Employee Number:
218Description
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.7 | |||||
Equity-to-Asset | -0.07 | |||||
Debt-to-Equity | -10.84 | |||||
Debt-to-EBITDA | -1.73 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -7.52 | |||||
Beneish M-Score | -3.51 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -12.4 | |||||
3-Year EBITDA Growth Rate | 34 | |||||
3-Year EPS without NRI Growth Rate | 32.5 | |||||
3-Year FCF Growth Rate | 38.4 | |||||
3-Year Book Growth Rate | -42.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 20.19 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.03 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.57 | |||||
9-Day RSI | 50.21 | |||||
14-Day RSI | 48.85 | |||||
3-1 Month Momentum % | 33.56 | |||||
6-1 Month Momentum % | -22.02 | |||||
12-1 Month Momentum % | -56.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.61 | |||||
Quick Ratio | 2.92 | |||||
Cash Ratio | 2.22 | |||||
Days Inventory | 164.65 | |||||
Days Sales Outstanding | 47.99 | |||||
Days Payable | 39.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -32.5 | |||||
Shareholder Yield % | -18.8 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 67.25 | |||||
Operating Margin % | -41.84 | |||||
Net Margin % | -49.3 | |||||
EBITDA Margin % | -40.24 | |||||
FCF Margin % | -37.37 | |||||
OCF Margin % | -36.71 | |||||
ROE % | -664.53 | |||||
ROA % | -55.69 | |||||
ROIC % | -155.23 | |||||
3-Year ROIIC % | 21008 | |||||
ROC (Joel Greenblatt) % | -258.48 | |||||
ROCE % | -62.24 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.5 | |||||
EV-to-EBIT | -1.57 | |||||
EV-to-EBITDA | -1.62 | |||||
EV-to-Revenue | 0.65 | |||||
EV-to-Forward-Revenue | 0.66 | |||||
EV-to-FCF | -1.74 | |||||
Price-to-GF-Value | 0.48 | |||||
Earnings Yield (Greenblatt) % | -63.69 | |||||
FCF Yield % | -84.33 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TELA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TELA Bio Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 80.814 | ||
| EPS (TTM) ($) | -0.79 | ||
| Beta | 3.6538 | ||
| 3-Year Sharpe Ratio | -0.86 | ||
| 3-Year Sortino Ratio | -1.11 | ||
| Volatility % | 65.19 | ||
| 14-Day RSI | 48.85 | ||
| 14-Day ATR ($) | 0.106147 | ||
| 20-Day SMA ($) | 0.80981 | ||
| 12-1 Month Momentum % | -56.63 | ||
| 52-Week Range ($) | 0.5011 - 2.2 | ||
| Shares Outstanding (Mil) | 44.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TELA Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TELA Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 16:30 | In 128 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 127 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-11 16:30 | In 34 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 33 days | ||
| General meeting for 2026 | 2026-06-09 10:00 | 0.85 (-4.55%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 16:30 | 0.97 (-4.89%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 0.97 (-4.89%) | ||
| Annual report for 2025 | 2026-03-25 | 0.76 (-9.15%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-24 16:30 | 0.83 (+4.52%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-24 | 0.83 (+4.52%) |
Show
Entries
TELA Bio Inc Frequently Asked Questions
What is TELA Bio Inc(TELA)'s stock price today?
The current price of TELA is $0.80. The 52 week high of TELA is $2.20 and 52 week low is $0.50.
When is next earnings date of TELA Bio Inc(TELA)?
The next earnings date of TELA Bio Inc(TELA) is 2026-08-11 Est..
Does TELA Bio Inc(TELA) pay dividends? If so, how much?
TELA Bio Inc(TELA) does not pay dividend.
Guru Commentaries on NAS:TELA
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| SMIC Reports 2019 Annual Results | 2020-03-31 | ||
| Fosun Pharma Announces 2019 Annual Results | 2020-03-31 |
Articles on TELA Bio Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers